One of the primary risk factors for hepatocellular carcinoma (HCC) is the hepatitis B virus (HBV). Exosomes have a significant impact on the dissemination of HBV-infected HCC. This study aimed to screen HBV exosome-related hub genes in HCC for a better understanding of the HCC pathogenic mechanism. First, multiple HBV-induced HCC datasets were collected from the Gene Expression Omnibus (GEO) database, and the exosome-related gene set was obtained from relevant literature. Nine HBV-related HCC exosome hub genes (HP, C9, APOA1, PON1, TTR, LPA, FCN2, FCN3, and MBL2) were selected through differential analysis and network analysis. An analysis of the receiver operation characteristic (ROC) revealed that these genes had good diagnostic value. These hub genes were primarily enriched in biological processes such as the citrate cycle tca cycle, phenylalanine metabolism, and fatty acid metabolism, according to gene set enrichment analysis (GSEA). Furthermore, this study predicted the miRNA (hsa-miR-590-5p) targeting LPA, as well as 12 lncRNAs (AL121655, SAP30-DT, LINC00472, etc.) targeting hsa-miR-590-5p. Finally, nelarabine, methylprednisolone, and methylprednisolone were predicted to be possible medications that target the hub gene based on the CellMiner database. To sum up, this work was crucial for discovering new biomarkers and comprehending the function of exosome-related genes in the growth of HBV-infected HCC.
FangYMaHZhangX, et al.Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma. Eur J Med Chem2024; 264: 116047.
2.
ShivangiMKMishraGuptaS, et al.Clinical diagnosis of viral hepatitis: current status and future strategies. Diagn Microbiol Infect Dis2023; 108: 116151.
3.
MaHYYamamotoGXuJ, et al.IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol2020; 72: 946–959.
4.
LiaoJXieXWangN, et al.Formononetin promotes fatty acid beta-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1alpha/PPARalpha pathway. Phytomedicine2023; 124: 155285.
5.
YangXLiQLiuW, et al.Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment. Cell Mol Immunol2023; 20: 583–599.
6.
WangCKangHYiY, et al.Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis. J Transl Med2023; 21: 919.
7.
ChenJXuZHuangH, et al.SETD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells. JCI Insight2023; 8: e168375.
8.
AustinatMDunschRWittekindC, et al.Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer2008; 7: 21.
9.
ToyodaHKoshiyamaYYasudaS, et al.Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection. J Viral Hepat2023; 31: 137–142.
10.
ChenYYangYWangN, et al.beta-Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1-regulated Wnt/beta-catenin pathway. J Cell Mol Med2023; 28: e18072.
11.
PaskehMDAGhadyaniFHashemiM, et al.Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: promises and challenges. Pharmacol Res2023; 187: 106553.
12.
SunLXiSZhouZ, et al.Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor. Oncogene2022; 41: 732–744.
13.
LiuZDaiXWangT, et al.Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett2017; 400: 149–160.
14.
YangZTangNZhengM,et al.Exosomal long noncoding RNAs serve as biomarkers for liver disease. Turk J Gastroenterol2023; 34: 674–680.
15.
HazratiASoudiSMalekpourK, et al.Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications. Biomark Res2022; 10: 30.
16.
JiangWShiXSunL, et al.Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner. Int J Biol Sci2023; 19: 4571–4587.
17.
DengMWuSHuangP, et al.Engineered exosomes-based theranostic strategy for tumor metastasis and recurrence. Asian J Pharm Sci2023; 18: 100870.
18.
WangHWangRLuoL, et al.An exosome-based specific transcriptomic signature for profiling regulation patterns and modifying tumor immune microenvironment infiltration in triple-negative breast cancer. Front Immunol2023; 14: 1295558.
19.
GlitscherMSpannausIMBehrF, et al.The protease domain in HEV pORF1 mediates the replicase's localization to multivesicular bodies and its exosomal release. Cell Mol Gastroenterol Hepatol2024; 17: 589–605.
20.
KwasnikMSochaWCzechB, et al.Protein-coding region derived small RNA in exosomes from influenza A virus-infected cells. Int J Mol Sci2023; 24: 867.
21.
YinYZhaoYChenQ, et al.Dual roles and potential applications of exosomes in HCV infections. Front Microbiol2022; 13: 1044832.
22.
BukongTNMomen-HeraviFKodysK, et al.Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog2014; 10: e1004424.
23.
WangJCaoDYangJ. Exosomes in hepatitis B virus transmission and related immune response. Tohoku J Exp Med2020; 252: 309–320.
24.
YangYHanQHouZ, et al.Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol2017; 14: 465–475.
25.
TodorovaVKByrumSDMackintoshSG, et al.Exosomal MicroRNA and protein profiles of hepatitis B virus-related hepatocellular carcinoma cells. Int J Mol Sci2023; 24: 13098.
26.
DongJZhangRXiaY, et al.The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC. Front Immunol2023; 14: 1142319.
27.
XueJZhaoHFuY, et al.Integrated analysis of multiple transcriptomic data identifies ST8SIA6–AS1 and LINC01093 as potential biomarkers in HBV–associated liver cancer. Oncol Lett2023; 25: 185.
28.
MelisMDiazGKleinerDE, et al.Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J Transl Med2014; 12: 230.
29.
PengWBaiSZhengM, et al.An exosome-related lncRNA signature correlates with prognosis, immune microenvironment, and therapeutic responses in hepatocellular carcinoma. Transl Oncol2023; 31: 101651.
30.
QiuPGuoQLinJ, et al.An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer. Sci Rep2022; 12: 22322.
31.
ZhuKTaoQYanJ, et al.Machine learning identifies exosome features related to hepatocellular carcinoma. Front Cell Dev Biol2022; 10: 1020415.
32.
AdugnaA. Histomolecular characterisation of hepatitis B virus induced liver cancer. Rev Med Virol2023; 33: e2485.
TourkochristouEAssimakopoulosSFThomopoulosK, et al.NAFLD And HBV interplay - related mechanisms underlying liver disease progression. Front Immunol2022; 13: 965548.
35.
RomanoLPaladiniSGalliC, et al.Hepatitis B vaccination. Hum Vaccin Immunother2015; 11: 53–57.
36.
RomanoLZanettiAR. Hepatitis B vaccination: a historical overview with a focus on the Italian achievements. Viruses2022; 14: 1515.
37.
HeWQGuoGNLiC. The impact of hepatitis B vaccination in the United States, 1999–2018. Hepatology2022; 75: 1566–1578.
38.
WongGLHuiVWYipTC, et al.Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther2022; 56: 869–877.
39.
YuSZhouLFuJ, et al.H-TEX-mediated signaling between hepatocellular carcinoma cells and macrophages and exosome-targeted therapy for hepatocellular carcinoma. Front Immunol2022; 13: 997726.
40.
DelangheJRDelrueCSpeeckaertR,et al.Unlocking the link between haptoglobin polymorphism and noninfectious human diseases: insights and implications. Crit Rev Clin Lab Sci2023; 61: 1–23.
41.
XieZHuangJLiY, et al.Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma. Sci Rep2023; 13: 18799.
42.
LiLShenYXuX, et al.Tracing and exploring the evolutionary origin and systematic function of fish complement C9. Mol Genet Genomics2021; 296: 665–676.
43.
LiuZYangMShuH,et al.A novel prognostic and therapeutic target biomarker based on complement-related gene signature in gastric cancer. Transl Cancer Res2023; 12: 3565–3580.
44.
BaeJSPasajeCFParkBL, et al.Genetic analysis of complement component 9 (C9) polymorphisms with clearance of hepatitis B virus infection. Dig Dis Sci2011; 56: 2735–2741.
45.
WangYChenSXiaoX, et al.Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma. Precis Clin Med2023; 6: pbad021.
46.
ZhangYYingXZhaoQ, et al.Identification of protein expression changes in hepatocellular carcinoma through iTRAQ. Dis Markers2020; 2020: 2632716.
47.
YuZOuQChenF, et al.Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J Transl Med2018; 16: 327.
48.
ZhangHLiuJ. Lifestyle factors, glycemic traits, and lipoprotein traits and risk of liver cancer: a Mendelian randomization analysis. Sci Rep2024; 14: 8502.
49.
PKDMalikSJMR, et al.Novel mutations in transthyretin gene associated with hepatocellular carcinoma. Mol Carcinog2018; 57: 70–77.
50.
TsimikasS. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol2017; 69: 692–711.
51.
FeingoldKR, et al.Introduction to Lipids and Lipoproteins. In: FeingoldKRAnawaltBBlackmanMRBoyceAChrousosGCorpasE (eds) Endotext. South Dartmouth (MA), 2000.
52.
LippiGFranchiniMSalvagnoGL,et al.Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev2007; 33: 427–436.
53.
DebikJSchaferHAndreassenT, et al.Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study. Br J Cancer2022; 127: 1515–1524.
54.
ZeljkovicAVekicJMihajlovicM, et al.Revealing the role of high-density lipoprotein in colorectal cancer. Int J Mol Sci2021; 22: 3352.
55.
ChaudharyJBowerJCorbinIR. Lipoprotein drug delivery vehicles for cancer: rationale and reason. Int J Mol Sci2019; 20: 6327.
56.
Pope 3rdEDKimbroughEOVemireddyLP, et al.Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets2019; 23: 473–483.
57.
AlannanMFayyad-KazanHTrezeguetV,et al.Targeting lipid metabolism in liver cancer. Biochemistry2020; 59: 3951–3964.
58.
YalamanogluADeuelJWHuntRC, et al.Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease. Am J Physiol Lung Cell Mol Physiol2018; 315: L765–LL74.
59.
TschoppJMollnesTE. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci U S A1986; 83: 4223–4227.
60.
MorrisGPuriBKBortolasciCC, et al.The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. Neurosci Biobehav Rev2021; 125: 244–263.
61.
LiaoHYangJXuY, et al.Mannose-binding Lectin 2 as a potential therapeutic target for hepatocellular carcinoma: multi-omics analysis and experimental validation. Cancers (Basel)2023; 15: 4900.
62.
XuCYDongJFChenZQ, et al.MiR-942-3p promotes the proliferation and invasion of hepatocellular carcinoma cells by targeting MBL2. Cancer Control2019; 26: 1073274819846593.
63.
SunLYuSDongC, et al.Comprehensive analysis of prognostic value and immune infiltration of ficolin family members in hepatocellular carcinoma. Front Genet2022; 13: 913398.
64.
WangLTZengQLJiangSL, et al.Ficolin-2: a potential immune-related therapeutic target with low expression in liver cancer. Front Oncol2022; 12: 987481.
65.
WangSSongZTanB, et al.Identification and validation of hub genes associated with hepatocellular carcinoma via integrated bioinformatics analysis. Front Oncol2021; 11: 614531.
66.
LaiXWuYKHongGQ, et al.A novel gene signature based on CDC20 and FCN3 for prediction of prognosis and immune features in patients with hepatocellular carcinoma. J Immunol Res2022; 2022: 9117205.
67.
KaurHDhallAKumarR,et al.Identification of platform-independent diagnostic biomarker panel for hepatocellular carcinoma using large-scale transcriptomics data. Front Genet2019; 10: 1306.
68.
TodiscoSConvertiniPIacobazziV,et al.TCA Cycle rewiring as emerging metabolic signature of hepatocellular carcinoma. Cancers (Basel)2019; 12: 68.
69.
FukudaHEbaraMOkuyamaM, et al.Increased metabolizing activities of the tricarboxylic acid cycle and decreased drug metabolism in hepatocellular carcinoma. Carcinogenesis2002; 23: 2019–2023.
70.
WanSWuYZhouX, et al.Polymorphisms in genes of tricarboxylic acid cycle key enzymes are associated with early recurrence of hepatocellular carcinoma. PLoS One2015; 10: e0124471.
71.
WigginsTKumarSMarkarSR, et al.Tyrosine, phenylalanine, and tryptophan in gastroesophageal malignancy: a systematic review. Cancer Epidemiol Biomarkers Prev2015; 24: 32–38.
72.
LiuNLiuCYangY, et al.Xiao-Xu-Ming decoction prevented hemorrhagic transformation induced by acute hyperglycemia through inhibiting AGE-RAGE-mediated neuroinflammation. Pharmacol Res2021; 169: 105650.
73.
WangBZhangHChenYF, et al.Acyl-CoA thioesterase 9 promotes tumour growth and metastasis through reprogramming of fatty acid metabolism in hepatocellular carcinoma. Liver Int2022; 42: 2548–2561.
74.
ZhangTZhangYLiuJ, et al.MicroRNA-377-3p inhibits hepatocellular carcinoma growth and metastasis through negative regulation of CPT1C-mediated fatty acid oxidation. Cancer Metab2022; 10: 2.
75.
JiaGTangYDengG, et al.miR-590-5p promotes liver cancer growth and chemotherapy resistance through directly targeting FOXO1. Am J Transl Res2019; 11: 2181–2193.
76.
ChenMWuLTuJ, et al.miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine2018; 35: 142–154.
77.
ChenFHeLQiuL, et al.Circular RNA CircEPB41L2 functions as tumor suppressor in hepatocellular carcinoma through sponging miR-590-5p. Cancer Manag Res2021; 13: 2969–2981.
78.
ZhangZWangSLiuW. EMT-related long non-coding RNA in hepatocellular carcinoma: a study with TCGA database. Biochem Biophys Res Commun2018; 503: 1530–1536.
79.
ChenCZhengQKangW,et al.Long non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell proliferation, migration and invasion through miR-93-5p/PDCD4 pathway. Clin Res Hepatol Gastroenterol2019; 43: 436–445.
80.
LinRXZhanGFWuJC, et al.LncRNA SNHG14 Sponges miR-206 to affect proliferation, apoptosis, and metastasis of hepatocellular carcinoma cells by regulating SOX9. Dig Dis Sci2022; 67: 936–946.
81.
ZhangHXuHBKurbanE,et al.LncRNA SNHG14 promotes hepatocellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling. Cell Death Dis2020; 11: 646.
82.
LiuXTanYZhangC, et al.NAT10 Regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep2016; 17: 349–366.
83.
WangYDaiJZengY, et al.E3 ubiquitin ligases in breast cancer metastasis: a systematic review of pathogenic functions and clinical implications. Front Oncol2021; 11: 752604.
84.
ZhangCYangYWangK, et al.The systematic analyses of RING finger gene signature for predicting the prognosis of patients with hepatocellular carcinoma. J Oncol2022; 2022: 2466006.
85.
KongSXueHLiY, et al.The long noncoding RNA OTUD6B-AS1 enhances cell proliferation and the invasion of hepatocellular carcinoma cells through modulating GSKIP/Wnt/beta-catenin signalling via the sequestration of miR-664b-3p. Exp Cell Res2020; 395: 112180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
